NewYork-Presbyterian establishes glioblastoma research center

NewYork-Presbyterian established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma.

Staff of the center — launched with an initial $5 million gift from NewYork-Presbyterian life trustee William Rhodes — will conduct research and provide the latest treatments to patients with glioblastoma and other brain cancers.

The center is named after Rhodes’ wife, Louise Tilzer-Rhodes, who died of glioblastoma in June.

“Glioblastoma has had a profound impact on my family and countless others,” Rhodes said in a press release. “It’s so important that we bring together and empower the brightest minds to bring new therapies — and one day, a cure — to patients.”

The center will follow a three-pronged approach that emphasizes multidisciplinary, research-driven patient care, with a focus on genomic and precision medicine; translational research intended to quickly advance promising therapies from the bench to the bedside; and clinician and scientist education, including the creation of new fellowships.

“Thanks to the generosity of Mr. Rhodes, we have an opportunity to make tremendous strides in our understanding and treatment of glioblastomas,” Steven J. Corwin, MD, president and CEO of NewYork-Presbyterian, said in the press release.

The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma will be led by four renowned neuro-oncologists:

  • Jeffrey Bruce, MD, co-director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center;
  • Andrew Lassman, MD, chief of the division of neuro-oncology in the department of neurology and co-director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center;
  • Howard Fine, MD, the founding director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine; and
  • Rohan Ramakrishna, MD, a surgical neuro-oncologist in the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine.

NewYork-Presbyterian established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma.

Staff of the center — launched with an initial $5 million gift from NewYork-Presbyterian life trustee William Rhodes — will conduct research and provide the latest treatments to patients with glioblastoma and other brain cancers.

The center is named after Rhodes’ wife, Louise Tilzer-Rhodes, who died of glioblastoma in June.

“Glioblastoma has had a profound impact on my family and countless others,” Rhodes said in a press release. “It’s so important that we bring together and empower the brightest minds to bring new therapies — and one day, a cure — to patients.”

The center will follow a three-pronged approach that emphasizes multidisciplinary, research-driven patient care, with a focus on genomic and precision medicine; translational research intended to quickly advance promising therapies from the bench to the bedside; and clinician and scientist education, including the creation of new fellowships.

“Thanks to the generosity of Mr. Rhodes, we have an opportunity to make tremendous strides in our understanding and treatment of glioblastomas,” Steven J. Corwin, MD, president and CEO of NewYork-Presbyterian, said in the press release.

The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma will be led by four renowned neuro-oncologists:

  • Jeffrey Bruce, MD, co-director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center;
  • Andrew Lassman, MD, chief of the division of neuro-oncology in the department of neurology and co-director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center;
  • Howard Fine, MD, the founding director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine; and
  • Rohan Ramakrishna, MD, a surgical neuro-oncologist in the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine.